• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2025 Jun;19(6):e70117.
doi: 10.1111/irv.70117. Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study

Ah-Ra Kim[SUP] 1 [/SUP], Chiara Achangwa[SUP] 2 [/SUP], Hyeon Nam Do[SUP] 1 [/SUP], Eun Young Jang[SUP] 3 [/SUP], Yukyung Nam[SUP] 2 4 [/SUP], Seonghui Cho[SUP] 2 [/SUP], Taegu Kim[SUP] 2 [/SUP], Hye-Sook Jeong[SUP] 1 [/SUP], Gi-Eun Rhie[SUP] 5 [/SUP], Kyungwon Oh[SUP] 6 [/SUP], Seunghyun Lewis Kwon[SUP] 7 [/SUP], Seunghyeon Lee[SUP] 2 [/SUP], Junewoo Lee[SUP] 1 [/SUP], Sukhyun Ryu[SUP] 2 [/SUP]



Affiliations
Free article Abstract

Background: Monitoring immunity levels nationwide and identifying disparities are important to prepare for future pandemics. However, data regarding changes in the seroprevalence of SARS-CoV-2 and disparities in consecutive epidemic waves using existing surveillance systems are limited.
Methods: We conducted a cross-sectional serosurvey using 11,506 residual serum samples collected from the Korean National Health and Nutrition Examination Survey between January 2021 and December 2022. Antibodies to the SARS-CoV-2 spike (anti-S) protein, indicative of vaccination or past infection of SARS-CoV-2, and nucleocapsid (anti-N) protein, indicating infection, were quantified. Then, we applied post-stratification weighting through the bootstrap resampling based on the age and sex distribution of the South Korean population. We used regression models to identify any disparities in the seropositivity prevalence ratio (PR) across different epidemic waves of SARS-CoV-2 and demographics in the population.
Results: We identified that the anti-S seropositivity gradually increased after the COVID-19 vaccination rollout, whereas anti-N seropositivity increased after the SARS-CoV-2 Omicron variant was introduced in Korea. Anti-S seropositivity PR was 0.12-0.76 times lower in individuals < 18 years than in elderly individuals ≥ 65 years during Waves 4-5 (July 2021 to June 2022). Anti-N seropositivity PR was 1.25-1.83 times higher in individuals less than 64 years than in elderly individuals during Waves 5-7 (January 2022 to December 2022).
Conclusions: Our findings provide insights into the dynamic changes in immunity levels among the Korean population after the COVID-19 vaccine rollout and the introduction of the Omicron variant. Identifying the disparity in seroprevalence in the study population during the pandemic by using the existing surveillance system provides helpful information to develop future pandemic preparedness plans for the population.

Keywords: SARS‐CoV‐2; antibody; community cohort; disparity; sero‐surveillance; surveillance.

 
Back
Top Bottom